All In MedTech

Device Trial Radar · NCT05301816

PDN Post Market, Multicenter, Prospective, Global Clinical Study

A Post-Market, Multicenter, Prospective, Global Clinical Study to Evaluate the Real-world Experience of Spinal Cord Stimulation That Includes 10 kHz in the Management of Chronic Intractable Pain Associated With Diabetic Neuropathy.

Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

497

Planned (sponsor's estimate)

Start

Jul 5, 2022

Primary completion

Oct 2027

Study completion Oct 2028

Sponsor

Lead sponsor
Nevro CorpNot on our public-company list
Sponsor type
Industry
First posted
Mar 31, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this post-market study is to evaluate the real-world experience of Nevro's Spinal Cord Stimulation (SCS) therapy in patients with chronic, intractable leg pain due to painful diabetic neuropathy (PDN). This is a multicenter, prospective, observational global study, that will partner diabetes management teams with pain physicians to provide an interdisciplinary treatment regimen for PDN patients. Outcomes will be assessed via standardized assessments.

Conditions

  • Diabetic Neuropathy, Painful

Interventions

  • Spinal Cord Stimulator (SCS)Device

    Spinal cord stimulation system (SCS) is an approved system to manage chronic intractable pain of the limbs and/or leg by delivering electrical stimulation using implantable leads and rechargeable implantable pulse generator (IPG) with 16 output channels. The IPG is implanted in a subcutaneous pocket and is capable of stimulating the spinal cord nerves when used with one or two 8-contact percutaneous or paddle leads.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Trial success rate/Responder rateTime frame: 2 weeks
  2. Patient-reported overall pain reliefTime frame: 12 months
  3. Leg painTime frame: 12 months

3 more outcomes with a free account

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Neuroversion, Inc.

    Anchorage, Alaska

  • Michigan Pain Specialists

    Ann Arbor, Michigan

  • Henry Ford Health

    West Bloomfield, Michigan

5 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.